Stay updated with the latest trastuzumab news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on trastuzumab topics.
New Delhi: What if doctors could tell, right at the time of breast cancer diagnosis, which patient is more likely to face heart problems years later? A new study in JAMA Oncology suggests that may soon be possible.The study, which followed more than 26,000 women with early-stage breast cancer, developed a risk prediction model that can identify those most likely to develop heart failure or cardiomyopathy -- two serious long-term complications of cancer treatment. Researchers found that the model ...Read More >
FDA Approves Kirsty (insulin aspart-xjhz), an Interchangeable Biosimilar to NovoLog BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India: July 15, 2025 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (FDA) has approved Kirsty™ (Insulin Aspart-xjhz), 100 units/mL as the first and only interchangeable* biosimilar to NovoLog® (Insulin ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.